相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
Brandon Essink et al.
CLINICAL INFECTIOUS DISEASES (2022)
Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021
Stephanie Perniciaro et al.
CLINICAL INFECTIOUS DISEASES (2022)
The epidemiological features of pediatric viral respiratory infection during the COVID-19 pandemic in Taiwan
Hao-Ting Hsu et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2022)
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Miwako Kobayashi et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Off-season RSV epidemics in Australia after easing of COVID-19 restrictions
John-Sebastian Eden et al.
NATURE COMMUNICATIONS (2022)
Incidence of acute lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019, estimated using both a prospective and retrospective methodology
Catherine Hyams et al.
BMJ OPEN (2022)
Experimental Human Pneumococcal Colonization in Older Adults Is Feasible and Safe, Not Immunogenic
Hugh Adler et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
A global agenda for older adult immunization in the COVID-19 era: A roadmap for action
Lois A. Privor-Dumm et al.
VACCINE (2021)
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK : a transmission model-based future scenario analysis and economic evaluation
Frank G. Sandmann et al.
LANCET INFECTIOUS DISEASES (2021)
Potential resurgence of respiratory syncytial virus in Canada
Pascal M. Lavoie et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2021)
Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France
Jacques Fourgeaud et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)
A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK
Andrew Vyse et al.
EXPERT REVIEW OF VACCINES (2021)
Mortality and readmission in the year following hospitalization for pneumonia among US adults
Ahuva Averin et al.
RESPIRATORY MEDICINE (2021)
Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021
Sonja J. Olsen et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Re-emergence of invasive pneumococcal disease (IPD) and increase of serotype 23B after easing of COVID-19 measures, Switzerland, 2021
Carlo Casanova et al.
EMERGING MICROBES & INFECTIONS (2021)
Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis
Ting Shi et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18
Harry Pick et al.
THORAX (2020)
Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective Observational Cohort Study, 2014-2018
Zahin Amin-Chowdhury et al.
CLINICAL INFECTIOUS DISEASES (2020)
Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program
Charles Stoecker et al.
VACCINE (2020)
The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections
Rachel E. Baker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England
James Campling et al.
BMJ OPEN RESPIRATORY RESEARCH (2020)
Protective effect of PCV vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling colonisation density
E. L. German et al.
VACCINE (2019)
A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands
Bradford D. Gessner et al.
VACCINE (2019)
Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis
John M. McLaughlin et al.
VACCINE (2019)
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Almea Matanock et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies
Heather L. Sings et al.
CLINICAL INFECTIOUS DISEASES (2019)
Pneumonia incidence trends in UK primary care from 2002 to 2017: population-based cohort study
Xiaohui Sun et al.
EPIDEMIOLOGY AND INFECTION (2019)
The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England
J. Campling et al.
PNEUMONIA (2019)
Estimating the opportunity costs of bed-days
Frank G. Sandmann et al.
HEALTH ECONOMICS (2018)
Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients
Frank G. Sandmann et al.
CLINICAL INFECTIOUS DISEASES (2018)
Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study
Shamez N. Ladhani et al.
LANCET INFECTIOUS DISEASES (2018)
Pneumococcal Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and RCT Reports
Hamid Latifi-Navid et al.
SCIENTIFIC REPORTS (2018)
Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England andWales
Abdelmajid Djennad et al.
ECLINICALMEDICINE (2018)
Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study
Motoi Suzuki et al.
LANCET INFECTIOUS DISEASES (2017)
Moving beyond traditional valuation of vaccination: Needs and opportunities
David E. Bloom et al.
VACCINE (2017)
The immunological mechanisms that control pneumococcal carriage
Simon P. Jochems et al.
PLOS PATHOGENS (2017)
Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies
Myint Tin Tin Htar et al.
PLOS ONE (2017)
Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea
Jung Yeon Heo et al.
PLOS ONE (2017)
The impact of community-acquired pneumonia on the health-related quality-of-life in elderly
Marie-Jose J. Mangen et al.
BMC INFECTIOUS DISEASES (2017)
Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort
P. K. Myint et al.
EPIDEMIOLOGY AND INFECTION (2016)
Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease
G. J. Hughes et al.
EPIDEMIOLOGY AND INFECTION (2016)
Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States
Charles Stoecker et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2016)
Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?
Mark Jit et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2016)
Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England
Albert Jan van Hoek et al.
PLOS ONE (2016)
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
Neil French et al.
MALAWI MEDICAL JOURNAL (2016)
First Human Challenge Testing of a Pneumococcal Vaccine Double-Blind Randomized Controlled Trial
Andrea M. Collins et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Chamira Rodrigo et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
Marie-Josee J. Mangen et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
Pauline A. Waight et al.
LANCET INFECTIOUS DISEASES (2015)
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
M. J. M. Bonten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
Shu-ling Hoshi et al.
PLOS ONE (2015)
Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study
Helmut Ostermann et al.
BMC PULMONARY MEDICINE (2014)
Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in US Older Adults
Kenneth J. Smith et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2013)
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
Lisa A. Jackson et al.
VACCINE (2013)
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
Bo-Hyun Cho et al.
VACCINE (2013)
Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy
Sara Boccalini et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Vaccines for preventing pneumococcal infection in adults
Sarah Moberley et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
Albert Jan van Hoek et al.
JOURNAL OF INFECTION (2012)
Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
Nick J. Andrews et al.
VACCINE (2012)
Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
Alexander Kuhlmann et al.
HEALTH ECONOMICS REVIEW (2012)
Using Health State Utility Values from the General Population to Approximate Baselines in Decision Analytic Models when Condition-Specific Data are Not Available
Roberta Ara et al.
VALUE IN HEALTH (2011)
A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults.
Neil French et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis
Kenneth J. Smith et al.
VACCINE (2008)
Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia
Jennie Johnstone et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries
S. M. A. A. Evers et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2007)
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection
KP Klugman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: Role of comorbid conditions and race
JE Sisk et al.
ANNALS OF INTERNAL MEDICINE (2003)
Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly
AM Fry et al.
VACCINE (2002)
分享论文
